Etanercept ( @entity13469 ) has been widely applied in the treatment of @entity1691 ( @entity1691 ). As the use of @entity13469 has increased, associated adverse effects have been reported frequently. Previous meta-analyses have focused on comparing the differences in clinical outcomes between @entity13469 and placebo (PBO). The present meta-analysis evaluated @entity23 ( @entity23 ) to compare the effects of @entity13469 and a PBO or @entity3378 (SSZ) in @entity1 with @entity1691 . The study population characteristics and the main results, including the Assessment in @entity1691 20% response (ASAS 20), the Bath @entity1691 Activity Index (BASDAI) and the Bath @entity1691 Functional Index (BASFI), were extracted. The pooled odds ratios (ORs) or weighted mean differences (MDs) were calculated using a fixed or random effects model. Fifteen @entity23 ( @entity23 ) involving 2,194 subjects were included. Compared with a PBO, @entity13469 significantly improved the ASAS 20 [P<0.00001; OR, 8.25; 95% confidence interval (CI), 5.92-11.50], BASDAI (P<0.00001; @entity601 , -18.81; 95% CI, -24.47 to -13.15) and BASFI (P<0.00001; standard @entity601 , -0.68; 95% CI, -0.85 to -0.50). In comparison with SSZ, @entity13469 significantly decreased the BASDAI (P<0.00001; @entity601 , -2.40; 95% CI, -2.89 to -1.90) and @entity1851 ( @entity1851 ) levels (P<0.0001; @entity601 , -8.01; 95% CI, -11.73 to -4.29). The most common adverse effect of @entity13469 was an injection site reaction. This meta-analysis shows that @entity13469 monotherapy is effective in improving physical function and reducing disease activity in @entity1 with @entity1691 . Compared with SSZ, @entity13469 markedly decreased the BASDAI and @entity1851 levels. However, the efficacy of @entity13469 in treating @entity1691 requires further evaluation by more @entity23 in a larger population of @entity1 prior to recommending @entity13469 as a substitute for synthetic disease-modifying antirheumatic drug (DMARD) monotherapy, or combinations of synthetic DMARDs.

Etanercept in the treatment of XXXX : A systematic review and meta-analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity13469 :: ('CHEBI:60072', 'Chemical') :: ['ETN'] @entity23 :: ('MESH:D007174', 'Disease') :: ['randomised controlled trials', 'RCTs'] @entity1691 :: ('MESH:D013167', 'Disease') :: ['ankylosing spondylitis', 'AS', 'AS Disease'] @entity601 :: ('MESH:D009436', 'Disease') :: ['MD'] @entity3378 :: ('MESH:D012460', 'Chemical') :: ['sulfasalazine'] @entity1851 :: ('1401', 'Gene') :: ['C-reactive protein', 'CRP']
@entity1691 :: (MESH:D013167,Disease) :: ['ankylosing spondylitis']
